New Targeted Therapy Bolsters Standard Treatment for Acute Myeloid Leukemia
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The...
The FDA has approved an inhibitor of FLT3 for use across multiple phases of acute myeloid leukemia treatment. The...
New oral hormonal therapy offers alternative to injections for some women with metastatic disease.
The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and...
The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food...
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate...
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The...
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration...